The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population

With an estimated 2.2 million new cases and 1.8 million deaths in 2020, lung cancer accounts for approximately 1 in 10 cancers cases and 1 in 5 cancer deaths worldwide[1]. Precision oncology enables targeted therapies to decrease tumor burden and symptoms, and improve survival outcomes and quality of life for patients with specific oncogenic driver alterations[2 –4]. There is an expanding list of approved targeted therapies for clinically actionable biomarkers, including epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) and Proto-oncogene tyrosine-protein kinase (ROS1) rearrangements, replacement of valine (V) by glutamic acid (E) at position 600 for B-Raf proto-oncogene serine/threonine kinase (BRAF V600E), glycine 12 to cysteine for Kirsten rat sarcoma viral oncogene homologue (KRAS G12C) mutations, mesenchymal epithelial transition factor (MET) exon 14 alterations, and neurotrophic tropomyosin receptor kinase (NT RK) and RET proto-oncogene (RET) rearrangements, and human epidermal growth factor receptor 2 (HER2) exon 20 insertion mutations[3,4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research